- Home
- BHVN vs RCUS Comparison
BHVN vs RCUS Comparison
Compare BHVN & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BHVN
- RCUS
- Stock Information
- Founded
- BHVN 2013
- RCUS 2015
- Country
- BHVN United States
- RCUS United States
- Employees
- BHVN N/A
- RCUS N/A
- Industry
- BHVN Biotechnology: Pharmaceutical Preparations
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- BHVN Health Care
- RCUS Health Care
- Exchange
- BHVN Nasdaq
- RCUS Nasdaq
- Market Cap
- BHVN 1.5B
- RCUS 1.2B
- IPO Year
- BHVN 2017
- RCUS 2018
- Fundamental
- Price
- BHVN $13.85
- RCUS $11.51
- Analyst Decision
- BHVN Strong Buy
- RCUS Buy
- Analyst Count
- BHVN 15
- RCUS 8
- Target Price
- BHVN $56.07
- RCUS $20.71
- AVG Volume (30 Days)
- BHVN 2.1M
- RCUS 730.3K
- Earning Date
- BHVN 11-11-2025
- RCUS 11-05-2025
- Dividend Yield
- BHVN N/A
- RCUS N/A
- EPS Growth
- BHVN N/A
- RCUS N/A
- EPS
- BHVN N/A
- RCUS N/A
- Revenue
- BHVN N/A
- RCUS $262,000,000.00
- Revenue This Year
- BHVN N/A
- RCUS N/A
- Revenue Next Year
- BHVN $2,002.87
- RCUS N/A
- P/E Ratio
- BHVN N/A
- RCUS N/A
- Revenue Growth
- BHVN N/A
- RCUS 6.07
- 52 Week Low
- BHVN $12.79
- RCUS $6.50
- 52 Week High
- BHVN $55.70
- RCUS $18.98
- Technical
- Relative Strength Index (RSI)
- BHVN 40.24
- RCUS 60.02
- Support Level
- BHVN $13.63
- RCUS $11.04
- Resistance Level
- BHVN $17.05
- RCUS $12.05
- Average True Range (ATR)
- BHVN 0.87
- RCUS 0.58
- MACD
- BHVN -0.23
- RCUS 0.03
- Stochastic Oscillator
- BHVN 4.42
- RCUS 63.59
About BHVN Biohaven Ltd.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.